TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21261200

Group type: EXPERIMENTAL
Intervention: Health and nutrition education intervention (n=195) through personal discussion sessions and lane approach
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (n=175)
Number of subjects: 370
Study: 18285545

Group type: EXPERIMENTAL
Intervention: Standard-risk group (35% of patients)
Number of subjects: 2169

Group type: EXPERIMENTAL
Intervention: Medium-risk group (53% of patients)
Number of subjects: 2169

Group type: EXPERIMENTAL
Intervention: High-risk group (12% of patients)
Number of subjects: 2169

Group type: COMPARATOR
Intervention: Omission of preventive cranial irradiation in non-T-ALL medium-risk patients
Number of subjects: 2169

Group type: COMPARATOR
Intervention: Comparison with previous trial ALL-BFM 90
Number of subjects: 2169
Study: 15882226

Group type: EXPERIMENTAL
Intervention: Behavioural educational intervention based on autoregulation theory
Number of subjects: 30

Group type: COMPARATOR
Intervention: Regular treatment based on instruction of proper prophylactic dental care
Number of subjects: 30
Study: 12563046

Group type: EXPERIMENTAL
Intervention: Selective head cooling with rectal temperature maintained at 35.0 degrees C
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Selective head cooling with rectal temperature maintained at 34.5 degrees C
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normothermic control group
Number of subjects: 26
Study: 10668583

Group type: EXPERIMENTAL
Intervention: Cefepime (1 g b.i.d.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ceftazidime (1 g t.i.d.)
Number of subjects: 50
Study: 9080244

Group type: EXPERIMENTAL
Intervention: Computer charting of physiological parameters
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cotside display of computer data
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Computer data with artifact removal
Number of subjects: 101
Study: 8250520

Group type: EXPERIMENTAL
Intervention: Pentasa (mesalazine) 2 g/day
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 3472450

Group type: EXPERIMENTAL
Intervention: Oral salt loading (normal diet + 200 mmol NaCl/day for 4 weeks followed by normal diet + 400 mmol/day for 1 week)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30688673

Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES)
Number of subjects: 340
Study: 29380951

Group type: EXPERIMENTAL
Intervention: Low sex hormone condition (gonadotropin releasing hormone antagonist, aromatase inhibitor, and placebo gel)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Testosterone add‐back condition (testosterone gel)
Number of subjects: 11
Study: 24172767

Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (dGTE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19
Study: 22566311

Group type: EXPERIMENTAL
Intervention: 15 g/d I-PHGG (fiber group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Maltodextrin (placebo group)
Number of subjects: 60
Study: 19946034

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0
Study: 17950101

Group type: EXPERIMENTAL
Intervention: Intravenous glucose with amino acids
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous glucose without amino acids (control)
Number of subjects: 16
Study: 15677624

Group type: EXPERIMENTAL
Intervention: irinotecan/5‐FU/leucovorin (LV) (IFL)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: oxaliplatin/5‐FU/LV (FOLFOX4)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: oxaliplatin/irinotecan (IROX)
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Chemotherapy following resection
Number of subjects: 795

Group type: EXPERIMENTAL
Intervention: Radiofrequency-ablation (RFA)
Number of subjects: 795
Study: 12121731

Group type: EXPERIMENTAL
Intervention: Botulinum A toxin (100 IU in 4 ml of 9% saline)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Lidocaine (4 ml of 0.5%)
Number of subjects: 13
Study: 10501652

Group type: EXPERIMENTAL
Intervention: formoterol 24 microg + oxitropium bromide 200 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oxitropium bromide + formoterol 24 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: formoterol 12 microg + oxitropium bromide 200 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oxitropium bromide + formoterol 12 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: formoterol 12 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: formoterol 24 microg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: oxitropium bromide
Number of subjects: 16
Study: 7662601

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (first dose)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (second dose)
Number of subjects: 10
Study: 2811943

Group type: EXPERIMENTAL
Intervention: Systemic prednisone (0.4 to 0.5 mg/kg for one month, gradually withdrawn over three months)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Radioiodine treatment alone
Number of subjects: 52
Study: 768965

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylcellulose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30286300

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) executed twice a week
Number of subjects: 26

Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) and Continuous Endurance Training (CET)
Number of subjects: 26
Study: 28619114

Group type: EXPERIMENTAL
Intervention: smartphone-based monitoring system including an integrated feedback loop and context-aware cognitive behavioral therapy (CBT) modules
Number of subjects: 400

Group type: COMPARATOR
Intervention: standard treatment
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: smartphone-based monitoring system
Number of subjects: 400
Study: 25627322

Group type: EXPERIMENTAL
Intervention: Early application of the non-pneumatic anti-shock garment (NASG) at the Primary Health Center (PHC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Later application of the non-pneumatic anti-shock garment (NASG) at the Referral Hospital (RH)
Number of subjects: 0
Study: 23871290

Group type: EXPERIMENTAL
Intervention: Heparin thromboprophylaxis
Number of subjects: 3764
Study: 21211064

Group type: EXPERIMENTAL
Intervention: Weekly reminder and motivational text messages
Number of subjects: 198

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study: 19064504

Group type: EXPERIMENTAL
Intervention: Lower energy density meals served over 2 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Higher energy density meals served over 2 days
Number of subjects: 26
Study: 16424989

Group type: EXPERIMENTAL
Intervention: Laparoscopic linear cutting stapler used to divide short gastric vessels
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard method (divided between hemostats and ligated)
Number of subjects: 56
Study: 12939852

Group type: EXPERIMENTAL
Intervention: Nitrates and captopril
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Nitrates and enalapril
Number of subjects: 141

Group type: COMPARATOR
Intervention: Nitrates and placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Combination of treatment, infarct location, and enzyme level
Number of subjects: 141
Study: 11074202

Group type: EXPERIMENTAL
Intervention: PARAGON stent
Number of subjects: 688

Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 688
Study: 9185459

Group type: COMPARATOR
Intervention: Fentanyl 12.5 micrograms.h‐1 (Group C, control, n = 7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms.h‐1 (Group S2, n = 7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms.h‐1 (Group C2, n = 7)
Number of subjects: 21
Study: 8418700

Group type: EXPERIMENTAL
Intervention: Long-term endoscopic sclerotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Elective shunt surgery
Number of subjects: 60
Study: 3296637

Group type: EXPERIMENTAL
Intervention: Somatonorm
Number of subjects: 21

Group type: COMPARATOR
Intervention: Pituitary hGH
Number of subjects: 21
Study: 29570594

Group type: EXPERIMENTAL
Intervention: Low-Intensity Blood-Flow Restricted Exercise (LI BFR)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HI)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-Intensity Non-Blood-Flow Restricted Exercise (LI non-BFR)
Number of subjects: 10
Study: 27199475

Group type: EXPERIMENTAL
Intervention: Quarterly mass azithromycin distributions for trachoma for 1 year
Number of subjects: 24

Group type: COMPARATOR
Intervention: Delayed treatment
Number of subjects: 24
Study: 24851679

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-hydroxychloroquine
Number of subjects: 72
Study: 22323387

Group type: EXPERIMENTAL
Intervention: Grandio
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tetric Ceram
Number of subjects: 30
Study: 20637972

Group type: EXPERIMENTAL
Intervention: TB-402 (0.015, 0.1, 0.5, 2.5, 12.5, 37.5, 188, 620, or 1860 microg/kg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 56
Study: 18622504

Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15770115

Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg/day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 12451430

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg once daily for 11 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10702654

Group type: EXPERIMENTAL
Intervention: Initial pain assessment during hospitalization
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 6-month pain recollection
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: High emotional distress group
Number of subjects: 177
Study: 8938548

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Number of subjects: 10
Study: 1752602

Group type: EXPERIMENTAL
Intervention: Bromocriptine (10 patients randomized to receive this treatment)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hypoprolactinemic cycle group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hyperprolactinemic cycle group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Euprolactinemic cycle group
Number of subjects: 45
Study: 7234826

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2,400 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tolmetin (2,000 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Naproxen (750 mg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (four tablets daily)
Number of subjects: 25
Study: 31783597

Group type: EXPERIMENTAL
Intervention: Probiotics (Foodis Lactobacillus)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30024784

Group type: EXPERIMENTAL
Intervention: CPX-351
Number of subjects: 309

Group type: COMPARATOR
Intervention: 7+3 (conventional cytarabine plus daunorubicin)
Number of subjects: 309
Study: 28509517

Group type: EXPERIMENTAL
Intervention: Test group (oral health promotion package including pamphlet, baby toothbrush, fluoride toothpaste 1,000 mg/L, trainer cup)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control One (only pamphlet)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control Two (no intervention)
Number of subjects: 92
Study: 24816536

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% (0.5 mg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Remifentanil (1 µg/kg)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 µg/kg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 101
Study: 22772951

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 199

Group type: COMPARATOR
Intervention: Gemcitabine plus cisplatin
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Posttreatment NLR
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: High pretreatment NLR that declined after treatment
Number of subjects: 199
Study: 19417230

Group type: EXPERIMENTAL
Intervention: Resistance training exercises (squat, seated leg curl, stiff leg dead lift, single leg stiff leg dead lift, good morning, Russian curl)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Resistance training exercises
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Strength matched resistance training exercises
Number of subjects: 34
Study: 17196493

Group type: EXPERIMENTAL
Intervention: Infraclavicular coracoid approach (IC group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Axillary approach (AX group)
Number of subjects: 60
Study: 15497667

Group type: EXPERIMENTAL
Intervention: Test formulation (clopidogrel bisulfate, 75 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Reference formulation (originator product)
Number of subjects: 36
Study: 11728786

Group type: EXPERIMENTAL
Intervention: Increased alcohol consumption among women
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 354
Study: 9443770

Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol daily for 8 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 25 mg captopril twice daily for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7946439

Group type: EXPERIMENTAL
Intervention: Fludarabine treatment
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: PCR method
Number of subjects: 4
Study: 3284267

Group type: EXPERIMENTAL
Intervention: halothane 0.5 MAC + 50% N2O
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: enflurane 0.5 MAC + 50% N2O
Number of subjects: 12

Group type: COMPARATOR
Intervention: halothane 1 MAC in oxygen
Number of subjects: 12

Group type: COMPARATOR
Intervention: enflurane 1 MAC in oxygen
Number of subjects: 12
Study: 29402954

Group type: EXPERIMENTAL
Intervention: Ozone followed by 38% H2O2 (20 min)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 38% H2O2 followed by ozone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group: Air followed by 38% H2O2 (20 min)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ozone (before or after H2O2)
Number of subjects: 45
Study: 27520090

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at 45 mmHg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Blood loss (BL) of 1000 ml
Number of subjects: 12
Study: 25002305

Group type: EXPERIMENTAL
Intervention: Mobile phone application
Number of subjects: 24

Group type: COMPARATOR
Intervention: Paper-based chart tool
Number of subjects: 24
Study: 22739998

Group type: EXPERIMENTAL
Intervention: Epidural steroid injection (ESI)
Number of subjects: 607

Group type: COMPARATOR
Intervention: No epidural steroid injection (No-ESI)
Number of subjects: 607
Study: 20877623

Group type: EXPERIMENTAL
Intervention: rAd5 vaccine alone (1×10^10 or 1×10^11 particle units)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: DNA prime - rAd5 boost
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: rAd5 vaccine alone
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: rAd5 vaccine alone or DNA prime - rAd5 boost
Number of subjects: 114
Study: 19035857

Group type: EXPERIMENTAL
Intervention: Annual screening with PSA (abnormal >4.0 ng/mL) and DRE
Number of subjects: 38349
Study: 17169935

Group type: EXPERIMENTAL
Intervention: Fit and Strong! intervention
Number of subjects: 215
Study: 14510719

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (400 microg bid)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (200 microg bid)
Number of subjects: 20
Study: 10525751

Group type: EXPERIMENTAL
Intervention: 200 mg sulpiride
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 400 mg sulpiride
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 8789975

Group type: EXPERIMENTAL
Intervention: Peanut allergy in siblings
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Skin prick testing for peanut
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Consumption of peanuts while pregnant or breastfeeding
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Atopy prevalence in generations
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Age of onset of peanut allergy
Number of subjects: 622
Study: 1807738

Group type: EXPERIMENTAL
Intervention: Interactive PlanAlyzer cases in anemia
Number of subjects: 328

Group type: COMPARATOR
Intervention: Text format content material (Control)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: PlanAlyzer cases in cardiology (after crossover)
Number of subjects: 328
Study: 6220672

Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Norfloxacin 800 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Norfloxacin 1200 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Norfloxacin 1600 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30017407

Group type: EXPERIMENTAL
Intervention: Serum HE4
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Serum CA125
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ROMA index
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: ROMA and HE4
Number of subjects: 373

Group type: COMPARATOR
Intervention: CA125
Number of subjects: 373
Study: 30072173

Group type: EXPERIMENTAL
Intervention: Music Group (daily listening to experiential/traditional music)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control Group (standard care only, no music therapy)
Number of subjects: 65
Study: 26911380

Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg/day)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Number of subjects: 279
Study: 25193990

Group type: EXPERIMENTAL
Intervention: Adjuvant cisplatin-based chemotherapy
Number of subjects: 1867
Study: 22269509

Group type: EXPERIMENTAL
Intervention: Talking on the phone
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Texting
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 138

Group type: COMPARATOR
Intervention: Undistracted
Number of subjects: 138
Study: 19126248

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dental devices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle advice
Number of subjects: 0
Study: 17903649

Group type: EXPERIMENTAL
Intervention: Patients without multiple cardiac risks (N = 2314)
Number of subjects: 4414

Group type: COMPARATOR
Intervention: Remaining excluded patients (N = 2100)
Number of subjects: 4414

Group type: COMPARATOR
Intervention: Randomized cohort (N = 462)
Number of subjects: 4414
Study: 15225081

Group type: EXPERIMENTAL
Intervention: Live modeling
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Corrected-error videotape
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Error-free videotape
Number of subjects: 40

Group type: COMPARATOR
Intervention: Handout alone
Number of subjects: 40
Study: 12560588

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-drug)
Number of subjects: 0
Study: 9640973

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 32
Study: 10138581

Group type: EXPERIMENTAL
Intervention: Intervention phase with dosage interval adjustment recommendations by staff pharmacists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline phase without dosage interval adjustment
Number of subjects: 0
Study: 2750685

Group type: EXPERIMENTAL
Intervention: Microcrystalline complex ferric orthophosphate (CFOP) labeled with 59Fe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Native Fe labeled with 55FeCl3
Number of subjects: 0
Study: 998534

Group type: EXPERIMENTAL
Intervention: Saturated diet with added cholesterol (291 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Polyunsaturated diet with added cholesterol (291 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saturated diet without added cholesterol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polyunsaturated diet without added cholesterol
Number of subjects: 12
Study: 29991034

Group type: EXPERIMENTAL
Intervention: High protein intake in infants (European CHOP Study)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted improvement in nutrient supply during pregnancy and infancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infant plasma AA and growth factors
Number of subjects: 0
Study: 27681865

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (cCRTX)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mutations in TP53
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mutated NOTCH1 and two functional KDR germline variants (rs2305948, rs1870377)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All genetic markers (TP53, NOTCH1, KDR)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Mutations in PI3K and RTK signaling pathways
Number of subjects: 175
Study: 25826770

Group type: COMPARATOR
Intervention: Continuous Energy Restriction (CER)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction (IER)
Number of subjects: 45
Study: 22980386

Group type: EXPERIMENTAL
Intervention: Formal education
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Informal education
Number of subjects: 477
Study: 20819508

Group type: EXPERIMENTAL
Intervention: Dachengqi decoction
Number of subjects: 40
Study: 18179368

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution
Number of subjects: 207

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 207
Study: 16513369

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0